Affimed has three active clinical programs focused on solid tumors and blood cancers, with lead candidate Acimtamig (AFM13) in development for patients with CD30-positive lymphomas. The company has collaborations with Artiva Biotherapeutics, Roivant Sciences Ltd., and Genentech for developing and commercializing novel ICE molecules in oncology.
Cyborg Score Rationale
Affimed operates in a promising immuno-oncology space with proprietary platform technology and strategic partnerships, but faces significant clinical-stage execution risk and severe equity dilution reflected in its collapsed market capitalization. The company's pipeline is advancing but remains early-stage.
Top Insights
Platform-driven approach: Affimed's proprietary ROCK® platform systematically generates multiple innate cell engager candidates with consistent development timelines
Strategic alliances reduce execution risk: Collaborations with established pharma (Genentech, Roivant) and emerging immunotherapy players (Artiva) provide clinical, commercial, and financial support
Lead program maturation: AFM13 (Acimtamig) has advanced through Phase I/II with encouraging responses; dual mechanism (monotherapy + NK cell combinations) expands addressable population
Severe equity distress: Stock trading near zero with minimal market cap ($2-3M) indicates severe shareholder dilution and potential delisting risk on NASDAQ
Named Competitors
AlloNK — Allogeneic NK cell therapy combined with AFM13 in clinical development
PD-L1 inhibitors — Atezolizumab checkpoint inhibitor combined with AFM24 in Phase IIa studies
NK cell therapies — Competing NK cell engagement and adoptive cell therapy approaches
Recent Developments
(2024) Lead programs AFM13 and AFM24 advanced with encouraging clinical data in Hodgkin Lymphoma and NSCLC
(2025) Company maintaining clinical operations and partnerships despite severe market valuation challenges
(2026 YTD) Stock trading at multi-year lows with market cap below $3M, indicating ongoing capitalization stress
Open the full interactive Affimed N.V. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.